CCL5 and neoplasm: Univariate Cox regression analysis showed that chemotherapy treatment in the subgroup with a tumor stage of pT3 + 4 with CCL5-negative ICs resulted in a 0.40-fold reduced risk of death (p = 0.019), a 0.45-fold reduced risk of disease-specific death (p = 0.044), and a 0.46-fold reduced risk of recurrence (p = 0.049; Table 7).